Allogeneic transplantation; Total body irradiation; Leukemia
Abstract :
[en] Limited clinical data are available to assess whether the sequencing of cyclophosphamide (Cy) and total body irradiation (TBI) changes outcomes. We evaluated the sequence in 1769 (CyTBI, n ¼ 948; TBICy, n ¼ 821) recipients of related or unrelated hematopoietic cell transplantation who received TBI (1200 to 1500 cGY) for acute leukemia from 2003 to 2010. The 2 cohorts were comparable for median age, performance score, type of leukemia, first complete remission, Philadelphia chromosomeepositive acute lymphoblastic leukemia, HLAmatched siblings, stem cell source, antithymocyte globulin use, TBI dose, and type of graft-versus-host disease (GVHD) prophylaxis. The sequence of TBI did not significantly affect transplantation-related mortality
(24% versus 23% at 3 years, P ¼.67; relative risk, 1.01; P ¼.91), leukemia relapse (27% versus 29% at 3 years, P ¼ .34; relative risk, .89, P ¼.18), leukemia-free survival (49% versus 48% at 3 years, P ¼.27; relative risk, .93; P ¼ .29), chronic GVHD (45% versus 47% at 1 year, P ¼.39; relative risk, .9; P ¼ .11), or overall survival (53% versus 52% at 3 years, P ¼.62; relative risk, .96; P ¼.57) for CyTBI and TBICy, respectively. Corresponding cumulative incidences of sinusoidal obstruction syndrome were 4% and 6% at 100 days (P ¼ .08), respectively. This study
demonstrates that the sequence of Cy and TBI does not impact transplantation outcomes and complications in patients with acute leukemia undergoing hematopoietic cell transplantation with myeloablative conditioning.
Yan R., Peters L.J., Travis E.L. Cyclophosphamide 24 hours before or after total body irradiation: effects on lung and bone marrow. Radiother Oncol 1991, 21:149-156.
Neilsen O.S., Safwat A., Overgaard J. The effect of sequence and time interval between cyclophosphamide and total body irradiation on lung and bone marrow damage following bone marrow transplantation in mice. Radiother Oncol 1993, 29:51-59.
Lowenthal E., Weiss L., Samuel S., et al. Optimization of conditioning therapy for leukemia prior to BMT. I. Optimal synergism between cyclophosphamide and total body irradiation for eradication of murine B cell leukemia (BCL1). Bone Marrow Transplant 1993, 12:109-113.
Thomas E.D., Buckner C.D., Rudolph R.H., et al. Allogeneic marrow grafting for hematologic malignancy using HLA matched donor-recipient sibling pairs. Blood 1971, 38:267-287.
Clift R.A., Buckner C.D., Appelbaum F.R., et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990, 76:1867-1871.
Thomas E.D., Herman E.C., Greenough W.B., et al. Irradiation and marrow infusion in leukemia. Observations in five patients with acute leukemia treated by whole-body exposures of 1,400 to 2,000 roentgens and infusions of marrow. Arch Intern Med 1961, 107:829-845.
Thomas E.D., Buckner C.D., Banaji M., et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977, 49:511-533.
Giebel S., Miszczyk L., Slosarek K., et al. Extreme heterogeneity of myeloablative total body irradiation techniques in clinical practice: a survey of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Cancer 2014, 120:2760-2765.
Shank B., Hopfan S., Kim J.H., et al. Hyperfractionated total body irradiation for bone marrow transplantation: I. Early results in leukemia patients. Int J Radiat Oncol Biol Phys 1981, 1:1109-1115.
Pasquini M.C., Wang Z., Horowitz M., Gale R.P. 2010 Report from the Center for International Blood and Marrow Transplant Research (CIBMTR): Current Uses and Outcomes of Hematopoietic Cell Transplant for Blood and Bone Marrow Disorders. Clinical Transplants 2010 2011, The Terasaki Foundation Laboratory, Los Angeles. J.M. Cecka, P.I. Terazaki (Eds.).
Clark T.G., Altman D.G., De Stavola B.L. Quantification of the completeness of follow-up. Lancet 2002, 359:1309-1310.
Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075-4083.
Weisdorf D., Spellman S., Haagenson M., et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant 2008, 14:748-758.
McDonald G.B., Slattery J.T., Bouvier M.E., et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003, 101:2043-2048.
McCune J.S., Batchelder A., Guthrie K.A., et al. Personalized dosing of cyclophosphamide in the total body irradiation - cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy. Clin Pharmacol Ther 2009, 85:615-622.
Hassan M., Ljungman P., Ringdén O., et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 2000, 25:915-924.
Pearson A.E., Steel G.G. Chemotherapy in combination with pelvic irradiation: a time-dependence study in mice. Radiother Oncol 1984, 2:49-55.
Collis C.H., Steel G.G. Lung damage in mice from cyclophosphamide and thoracic irradiation: the effect of timing. Int J Radiat Oncol Biol Phys 1982, 9:685-689.
Marks D.I., Forman S.J., Blume K.G., et al. Acomparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. Biol Blood Marrow Transplant 2006, 12:438-453.